ArticleFrontiers in endocrinology2025
Visceral adiposity loss is associated with improvement in cardiometabolic markers: findings from a dietary intervention study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Trial
- Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis.Circulation research · 2026Review
- Digital-Assisted Nutritional Monitoring and Body Composition Changes in Aging Adults: A 6-Month Controlled Longitudinal Study.Nutrients · 2026Article
- Sex-Specific Cardiometabolic Profiles and Severity of Liver Fibrosis.JAMA network open · 2026Article
- VAT-Dependent Inflammatory Proteomic Signatures of Cardiometabolic Traits and Central Proteins.Research square · 2025Article
- Mediterranean diet adherence and tirzepatide: real-world evidence on adiposity indices and insulin resistance beyond weight loss.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Visceral adiposity is closely linked with cardiometabolic disorders, but evidence on the extent of visceral fat loss required for significant improvement in cardiometabolic markers remains limited. This study aims to investigate the association between visceral fat area (VFA) reductions and improvements in cardiometabolic markers following a 3-month dietary intervention. Methods: A total of 175 adults with overweight and obesity were involved in this non-randomized controlled trial. Data on sociodemographic, anthropometric, body composition and biochemistry were collected at baseline and after 3 months of intervention. The multiple logistic regression analysis was conducted to determine the association between VFA loss (no loss, < 5% loss, and ≥ 5% loss) and improvement in cardiometabolic markers. For each cardiometabolic marker, an improvement surpassing the minimum threshold of the third tertile was classified as a good improvement. Results: Compared to those with no VFA loss, participants with VFA loss of ≥ 5% were significantly associated with a higher improvement in waist circumference (OR 2.97, 95% CI 1.16-7.64), high-density lipoprotein cholesterol (HDL-C) (OR 4.19, 95% CI 1.58-11.14), triglycerides (OR 3.01, 95% CI 1.14-7.92), and glycated hemoglobin (HbA1C) (OR 2.95, 95% CI 1.12-7.79). Other than that, those with < 5% VFA loss were 3.6 times more likely to have a higher improvement in HDL-C compared to those with no VFA loss (OR 4.08, 95% CI 1.36-12.22). Conclusion: This study found that the magnitude of VFA loss is an independent determinant of improvements in cardiometabolic markers and should be set as a clear target when designing obesity prevention programs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.